IL109160A - Conjugates of proteins and bifunctional ligands method of their preparation and pharmaceutical compositions containing them - Google Patents

Conjugates of proteins and bifunctional ligands method of their preparation and pharmaceutical compositions containing them

Info

Publication number
IL109160A
IL109160A IL10916094A IL10916094A IL109160A IL 109160 A IL109160 A IL 109160A IL 10916094 A IL10916094 A IL 10916094A IL 10916094 A IL10916094 A IL 10916094A IL 109160 A IL109160 A IL 109160A
Authority
IL
Israel
Prior art keywords
conjugates
proteins
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL10916094A
Other languages
English (en)
Other versions
IL109160A0 (en
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of IL109160A0 publication Critical patent/IL109160A0/xx
Publication of IL109160A publication Critical patent/IL109160A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL10916094A 1993-03-29 1994-03-29 Conjugates of proteins and bifunctional ligands method of their preparation and pharmaceutical compositions containing them IL109160A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/038,416 US5612016A (en) 1988-04-01 1993-03-29 Conjugates of antibodies and bifunctional ligands

Publications (2)

Publication Number Publication Date
IL109160A0 IL109160A0 (en) 1994-06-24
IL109160A true IL109160A (en) 2000-06-01

Family

ID=21899823

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10916094A IL109160A (en) 1993-03-29 1994-03-29 Conjugates of proteins and bifunctional ligands method of their preparation and pharmaceutical compositions containing them

Country Status (7)

Country Link
US (1) US5612016A (xx)
EP (1) EP0691854A4 (xx)
JP (1) JPH08508488A (xx)
AU (1) AU672490B2 (xx)
CA (1) CA2158054C (xx)
IL (1) IL109160A (xx)
WO (1) WO1994022490A1 (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
DE19731741A1 (de) * 1997-07-23 1999-01-28 Deutsches Krebsforsch Konjugat zur Unterscheidung von krankhaftem und gesundem Gewebe
DE19835082A1 (de) * 1998-07-24 2000-02-03 Schering Ag Paramagnetische 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung für das Nekrose- und Infarkt-MR-Imaging
US6800437B1 (en) * 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
WO2003045546A1 (en) * 2001-11-27 2003-06-05 Prometic Biosciences Ltd. The use of metal-chelating adsorbents
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2003101495A1 (en) * 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
EP1689448B1 (en) 2003-12-01 2015-07-29 Immunomedics Inc. Method for preparing dota-antibody conjugates
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
CN102448494B (zh) 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
BRPI1013990A2 (pt) * 2009-05-06 2019-04-30 Biotest Ag método para tratar uma doença , e, combinação anticâncer
EP2456472B1 (en) * 2009-07-22 2024-03-27 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
US10088490B2 (en) 2010-08-20 2018-10-02 Siemens Healthcare Diagnostics Inc. Assay for analytes using multiple receptors
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2014137903A2 (en) 2013-03-08 2014-09-12 Genzyme Corporation Integrated continuous manufacturing of therapeutic protein drug substances
US10384078B2 (en) * 2013-10-15 2019-08-20 Ip Liberty Vision Corporation Polymeric radiation-sources
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
KR101477498B1 (ko) * 2014-02-21 2014-12-30 고려대학교 산학협력단 죽상동맥경화 영상화용 조성물 및 이를 이용한 죽상동맥경화 진단방법
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN104987386A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铅-纤维蛋白原螯合物及其制备方法和应用
CN104987411A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镉-IgA螯合物及其制备方法和应用
CN104987414A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镍-IgM螯合物及其制备方法和应用
CN105001322A (zh) * 2015-07-14 2015-10-28 上海拜豪生物科技有限公司 一种铬-高密度脂蛋白螯合物及其制备方法和应用
CN104987394A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种汞-极低密度脂蛋白螯合物及其制备方法和应用
CN104987388A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铅-白蛋白螯合物及其制备方法和应用
CN104987415A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铬-IgM螯合物及其制备方法和应用
CN105001323A (zh) * 2015-07-14 2015-10-28 上海拜豪生物科技有限公司 一种镍-极低密度脂蛋白螯合物及其制备方法和应用
CN105004685B (zh) * 2015-07-14 2018-02-16 上海拜豪生物科技有限公司 一种汞‑IgE螯合物及其制备方法和应用
CN104987402A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铅-血红蛋白螯合物及其制备方法和应用
CN104987396A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铅-极低密度脂蛋白螯合物及其制备方法和应用
CN105001321A (zh) * 2015-07-14 2015-10-28 上海拜豪生物科技有限公司 一种汞-纤维蛋白原螯合物及其制备方法和应用
CN105044009B (zh) * 2015-07-14 2018-04-03 上海拜豪生物科技有限公司 一种铬‑极低密度脂蛋白螯合物及其制备方法和应用
CN104987405B (zh) * 2015-07-14 2018-01-23 广东腾湃医疗投资管理有限公司 一种砷‑IgG螯合物及其制备方法和应用
CN105021550B (zh) * 2015-07-14 2018-01-05 上海拜豪生物科技有限公司 一种汞‑高密度脂蛋白螯合物及其制备方法和应用
CN104987409B (zh) * 2015-07-14 2018-01-05 上海拜豪生物科技有限公司 一种铅‑IgG螯合物及其制备方法和应用
CN104987387A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铬-纤维蛋白原螯合物及其制备方法和应用
CN104987404A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镍-IgG螯合物及其制备方法和应用
CN105021552B (zh) * 2015-07-14 2018-11-02 上海拜豪生物科技有限公司 一种镍-高密度脂蛋白螯合物及其制备方法和应用
CN105004684B (zh) * 2015-07-14 2018-04-03 上海拜豪生物科技有限公司 一种镍‑IgE螯合物及其制备方法和应用
CN104987407B (zh) * 2015-07-14 2018-01-05 上海拜豪生物科技有限公司 一种镉‑IgG螯合物及其制备方法和应用
CN105153299A (zh) * 2015-07-14 2015-12-16 上海拜豪生物科技有限公司 一种铅-IgM螯合物及其制备方法和应用
CN104987399A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-极低密度脂蛋白螯合物及其制备方法和应用
CN105037537A (zh) * 2015-07-14 2015-11-11 上海拜豪生物科技有限公司 一种铅-IgA螯合物及其制备方法和应用
CN104987412A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgE螯合物及其制备方法和应用
CN104987413A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgA螯合物及其制备方法和应用
CN105021553A (zh) * 2015-07-14 2015-11-04 上海拜豪生物科技有限公司 一种砷-高密度脂蛋白螯合物及其制备方法和应用
CN104987385A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镉-纤维蛋白原螯合物及其制备方法和应用
CN104987393A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镉-极低密度脂蛋白螯合物及其制备方法和应用
CN104987406A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种镍-IgA螯合物及其制备方法和应用
CN104987410A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铅-IgE螯合物及其制备方法和应用
CN105021549B (zh) * 2015-07-14 2018-02-16 上海拜豪生物科技有限公司 一种镍‑白蛋白螯合物及其制备方法和应用
CN105044006B (zh) * 2015-07-14 2018-04-03 上海拜豪生物科技有限公司 一种汞‑IgG螯合物及其制备方法和应用
CN105061586A (zh) * 2015-07-14 2015-11-18 上海拜豪生物科技有限公司 一种铅-低密度脂蛋白螯合物及其制备方法和应用
CN105044007B (zh) * 2015-07-14 2018-08-21 上海拜豪生物科技有限公司 一种镉-IgM螯合物及其制备方法和应用
CN104987398A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种铬-低密度脂蛋白螯合物及其制备方法和应用
CN105021554B (zh) * 2015-07-14 2019-03-22 上海拜豪生物科技有限公司 一种砷-IgM螯合物及其制备方法和应用
CN105037528A (zh) * 2015-07-14 2015-11-11 上海拜豪生物科技有限公司 一种镍-低密度脂蛋白螯合物及其制备方法和应用
CN105044008B (zh) * 2015-07-14 2018-01-05 上海拜豪生物科技有限公司 一种镉‑高密度脂蛋白螯合物及其制备方法和应用
CN104987397A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种汞-低密度脂蛋白螯合物及其制备方法和应用
CN105004683B (zh) * 2015-07-14 2019-03-01 上海拜豪生物科技有限公司 一种铬-IgE螯合物及其制备方法和应用
CN105044005B (zh) * 2015-07-14 2018-08-21 上海拜豪生物科技有限公司 一种铬-IgA螯合物及其制备方法和应用
CN105044004B (zh) * 2015-07-14 2018-01-05 上海拜豪生物科技有限公司 一种汞‑IgM螯合物及其制备方法和应用
CN104987395A (zh) * 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 砷-低密度脂蛋白螯合物及其制备方法和应用
CN105021548B (zh) * 2015-07-14 2018-04-03 上海拜豪生物科技有限公司 一种砷‑纤维蛋白原螯合物及其制备方法和应用
KR20210049155A (ko) 2018-08-31 2021-05-04 젠자임 코포레이션 멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
SE8302758L (sv) * 1983-05-17 1984-11-18 Pharmacia Ab Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5128119A (en) * 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
JP3070763B2 (ja) * 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識

Also Published As

Publication number Publication date
JPH08508488A (ja) 1996-09-10
AU6412394A (en) 1994-10-24
WO1994022490A1 (en) 1994-10-13
IL109160A0 (en) 1994-06-24
US5612016A (en) 1997-03-18
EP0691854A1 (en) 1996-01-17
CA2158054A1 (en) 1994-10-13
AU672490B2 (en) 1996-10-03
EP0691854A4 (en) 1997-03-05
CA2158054C (en) 2001-05-15

Similar Documents

Publication Publication Date Title
IL109160A (en) Conjugates of proteins and bifunctional ligands method of their preparation and pharmaceutical compositions containing them
IL114626A0 (en) 6-membered nitrogen-containing heteroaryl-oxazolidinones their preparation and pharmaceutical compositions containing them
IL120902A0 (en) Interferon conjugates their preparation and pharmaceutical compositions containing them
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
IL121234A0 (en) Heterocyclic-fused pyridines their preparation and pharmaceutical compositions containing them
IL110160A (en) Phosphopeptides their preparation and pharmaceutical compositions containing them
IL114578A0 (en) Amino purine-béta-D ribofuranuronamide derivatives their preparation pharmaceutical compositions containing them and their use
IL121235A0 (en) Bicyclic-fused pyridines their preparation and pharmaceutical compositions containing them
IL121236A0 (en) Cycloalkano-pyridines their preparation and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
IL111518A (en) Isoquinolines their preparation and pharmaceutical compositions containing them
IL114795A (en) N-benzylindole-and benzopyrazole derivatives their preparation and pharmaceutical compositions containing them
IL114925A0 (en) Glycinamide derivatives their preparation and pharmaceutical compositions containing them
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
IL86086A0 (en) Bifunctional proteins and pharmaceutical compositions containing them
IL117349A0 (en) N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them
IL115905A0 (en) Sordarin derivatives their preparation and pharmaceutical compositions containing them
IL119316A0 (en) Hydroxypyridinones their preparation and pharmaceutical compositions containing them
IL125710A0 (en) Arylglycinamide derivatives their preparation and pharmaceutical compositions containing them
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
IL118410A0 (en) Substituted camptothecin derivatives their preparation and pharmaceutical compositions containing them
IL117815A0 (en) Ascomycins their preparation and pharmaceutical compositions containing them
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
IL113484A0 (en) Viral proteins pharmaceutical compositions containing them their preparation and use
AP9600784A0 (en) Oxathiolanes method for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired